AZ in Hong Kong

AstraZeneca is a global pharmaceutical company harnessing the power of science to make health happen for people, society and the planet. We follow the science to create transformative change, primarily for the treatment of diseases in four main therapy areas - Oncology, Cardiovascular & Metabolic Disease, Respiratory and Rare Disease. We are also selectively active in the areas of autoimmunity, neuroscience and infection.

AstraZeneca Hong Kong oversees both the Hong Kong and Macau markets and attaches a strong importance to them. Since its inception in 1990, AstraZeneca Hong Kong has delivered many life-changing medicines that have transformed the lives of patients and have revolutionized disease treatment in Hong Kong and Macau. Over the years, we have been continually expanding our business in order to meet the growing demand of the markets.

To make health happen for as many people, in as many ways, as possible, we ensure that our medicines can reach the people that need them and minimise the economic burden of delivering them. We push the boundaries of science to deliver life-changing medicines for the world’s most serious health challenges. We ensure broad access to our life-changing medicines, working to ensure that every eligible person, no matter their personal circumstances, can be connected with the right treatment. We have provided different Patient Affordability Programs in collaboration with local associations in the past years. We are also working with different non-governmental organizations (NGOs) to provide patient empowerment programs in Respiratory, Diabetes, Cardiovascular and Cancer diseases.

Making health happen for society has never been more important as AstraZeneca Hong Kong works in partnership with governments and others to advance healthcare systems and economies. We continuously work to find new innovative ways to prevent threats to health, diagnose patients earlier and treat people in their homes and communities, reducing pressure on health systems. We have partnered with Hong Kong Science and Technology Parks Corporation in 2021 to launch a co-incubation programme to support biomedical startups in their mission to develop integrated oncology solutions to accelerate innovation in oncology, foster local biomedical technologies and enhance Hong Kong’s status as a leading biomedical innovation hub. We have launched more than 100 products, conducted over 100 clinical studies, including 30 breakthrough studies, treated over 5,000,000 patients and delivered the Young Health Programme, promoting mental health among youth by rugby training, to drive incremental societal health change in the past 30+ years.

As a trusted healthcare partner, AstraZeneca Hong Kong commits to making health happen for the planet as well. We take care of our physical environment in Hong Kong and ensure that we push the boundaries of health and medicine in ways that respect the planet. Via our internal ‘Eco-Keeper’ campaign, we aim to make our impact on the environment. In 2021, we have reduced electricity consumption by 20%, comparing to 2019, and supported electricity generated from local renewable energy sources in Hong Kong.

Our strategic priorities are to deliver growth and TA leadership, accelerate innovative science and be a great place to work. As we celebrate our past accomplishments, we are confident about the future– because of our people, our partners and our firm commitment to pushing the boundaries of science to deliver life-changing medicines. Looking ahead, we will continue focus on sustainable development and the delivery of a flow of new medicines that make a difference in the lives of patients in Hong Kong and around the world.

For more information about AstraZeneca, please go to: .

HK-7182 17/5/2022